AMIX on Nasdaq
Autonomix Medical, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Research and development | $7.1M | $4.7M |
| General and administrative | $9.9M | $6.9M |
| Total operating expenses | $17.0M | $11.6M |
| Loss from operations | -$17.0M | -$11.6M |
| Interest expense | $0 | -$176.0K |
| Interest income | $319.0K | $354.0K |
| Total other income, net | $319.0K | $178.0K |
| Loss before income taxes | -$16.7M | -$11.4M |
| Income taxes | $0 | $0 |
| Net loss | -$16.7M | -$11.4M |
| Loss per share - basic and diluted (in dollars per share) | -$2.32 | -$6.46 |
| Weighted average shares outstanding - basic and diluted (in shares) | 7.2M shares | 1.8M shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash and cash equivalents | $7.0M | $9.1M | |
| Other current assets | $577.0K | $473.0K | |
| Total current assets | $7.6M | $9.6M | |
| Property and equipment, net | $19.0K | $21.0K | |
| Deferred offering costs | $0 | $176.0K | |
| Total noncurrent assets | $19.0K | $197.0K | |
| Total Assets | $7.6M | $9.8M | |
| Accounts payable | $700.0K | $676.0K | |
| Accrued expenses | $1.0M | $1.0M | |
| Total current liabilities | $1.7M | $1.7M | |
| Total Liabilities | $1.7M | $1.7M | |
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and 2025, respectively | $0 | $0 | |
| Common stock, $0.001 par value, 500,000,000 shares authorized, 11,409,344 and 2,497,033 shares issued and outstanding as of March 31, 2026 and 2025, respectively | $11.0K | $2.0K | |
| Additional paid-in capital | $73.0M | $58.5M | |
| Accumulated deficit | -$67.1M | -$50.4M | |
| Total Stockholders' Equity | $5.9M | $8.1M | $7.6M |
| Total Liabilities and Stockholders' Equity | $7.6M | $9.8M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 500.0M shares | 500.0M shares | |
| Common stock, issued (in shares) | 11.4M shares | 2.5M shares | |
| Common stock, outstanding (in shares) | 11.4M shares | 2.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Net loss | -$16.7M | -$11.4M |
| Stock-based compensation | $529.0K | $1.6M |
| Stock option cancellations | $3.7M | $0 |
| Issuance of common stock for equity line of credit commitment fee | $267.0K | $0 |
| Depreciation and amortization expense | $12.0K | $183.0K |
| Issuance of common stock, net of discount for lack of marketability | $0 | $101.0K |
| Other current assets | -$104.0K | $310.0K |
| Accounts payable | $24.0K | $184.0K |
| Accrued expenses | -$27.0K | $746.0K |
| Net cash used in operating activities | -$12.3M | -$8.3M |
| Purchase of property and equipment | -$10.0K | -$14.0K |
| Net cash used in investing activities | -$10.0K | -$14.0K |
| Gross proceeds from issuance of common stock | $3.5M | $0 |
| Direct financing costs for issuance of common stock | -$141.0K | $0 |
| Gross proceeds from warrant inducement | $2.5M | $0 |
| Direct transaction costs for warrant inducement | -$291.0K | $0 |
| Gross proceeds from issuance and exercises of pre-funded warrants | $5.0M | $0 |
| Direct financing costs for issuance of pre-funded warrants | -$485.0K | $0 |
| Gross proceeds from issuance of common stock, pre-funded and common warrants | $0 | $10.0M |
| Direct transaction costs for issuance of common stock, pre-funded and common warrants | $0 | -$1.1M |
| Payment of issuance costs for registration statement | $0 | -$176.0K |
| Gross proceeds from exercise of warrants | $0 | $1.0K |
| Proceeds from sales of common stock | $0 | $2.0K |
| Net cash provided by financing activities | $10.2M | $8.8M |
| Net change in cash and cash equivalents | -$2.1M | $528.0K |
| Recognition of deferred financing costs associated with issuance of common stock | -$176.0K | $0 |
| Proceeds from cashless exercise of warrants | $1.0K | $39.0K |
| Warrants issued for equity issuance costs | $0 | $479.0K |
Recent filings
- Oct 13, 20263
- Sep 21, 20264 FORM 4 - SMITH, TRENT
- Sep 16, 20268-K
- Sep 16, 2026424B3
- Sep 15, 2026EFFECT
- Sep 14, 2026DEF 14A
- Sep 14, 2026DEFA14A
- Sep 11, 2026424B5
- Sep 8, 20264 FORM 4 - HAUSER, BRAD
- Sep 8, 20264 FORM 4 - BISSON, LORI
- Sep 8, 20264 FORM 4 - KLEMP, WALLY
- Sep 4, 2026S-3
- Sep 4, 2026PRE 14A
- Aug 26, 20268-K
- Aug 13, 202610-Q
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8